Teachers Retirement System of The State of Kentucky Takes $37.69 Million Position in Teva Pharmaceutical Industries Limited (NYSE:TEVA)

Teachers Retirement System of The State of Kentucky acquired a new position in shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA - Free Report) in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund acquired 1,710,000 shares of the company's stock, valued at approximately $37,689,000. Teachers Retirement System of The State of Kentucky owned 0.15% of Teva Pharmaceutical Industries at the end of the most recent quarter.

Several other hedge funds have also recently made changes to their positions in TEVA. Diversify Advisory Services LLC boosted its stake in shares of Teva Pharmaceutical Industries by 2.5% during the 4th quarter. Diversify Advisory Services LLC now owns 20,355 shares of the company's stock worth $426,000 after acquiring an additional 496 shares in the last quarter. Sanctuary Advisors LLC boosted its stake in shares of Teva Pharmaceutical Industries by 1.9% in the third quarter. Sanctuary Advisors LLC now owns 35,129 shares of the company's stock worth $601,000 after acquiring an additional 664 shares during the last quarter. Thrivent Financial for Lutherans raised its stake in Teva Pharmaceutical Industries by 0.3% in the 4th quarter. Thrivent Financial for Lutherans now owns 225,210 shares of the company's stock valued at $4,964,000 after purchasing an additional 699 shares during the last quarter. Townsquare Capital LLC lifted its holdings in Teva Pharmaceutical Industries by 2.1% in the 4th quarter. Townsquare Capital LLC now owns 40,162 shares of the company's stock valued at $885,000 after purchasing an additional 812 shares in the last quarter. Finally, Metis Global Partners LLC grew its holdings in shares of Teva Pharmaceutical Industries by 6.7% during the fourth quarter. Metis Global Partners LLC now owns 13,697 shares of the company's stock worth $302,000 after buying an additional 860 shares in the last quarter. 54.05% of the stock is owned by institutional investors and hedge funds.

Teva Pharmaceutical Industries Stock Up 0.6 %

Shares of TEVA stock traded up $0.09 during trading hours on Friday, reaching $14.81. 3,866,788 shares of the stock were exchanged, compared to its average volume of 9,914,560. Teva Pharmaceutical Industries Limited has a 12-month low of $12.47 and a 12-month high of $22.80. The business's fifty day moving average is $15.26 and its two-hundred day moving average is $17.58. The company has a debt-to-equity ratio of 2.97, a current ratio of 0.98 and a quick ratio of 0.75. The firm has a market capitalization of $16.79 billion, a P/E ratio of -10.21, a P/E/G ratio of 1.44 and a beta of 0.72.

Teva Pharmaceutical Industries (NYSE:TEVA - Get Free Report) last released its quarterly earnings data on Wednesday, January 29th. The company reported $0.70 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.69 by $0.01. Teva Pharmaceutical Industries had a positive return on equity of 42.46% and a negative net margin of 9.91%. As a group, research analysts expect that Teva Pharmaceutical Industries Limited will post 2.5 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of analysts have commented on TEVA shares. Bank of America cut their price objective on shares of Teva Pharmaceutical Industries from $23.00 to $20.00 and set a "buy" rating for the company in a report on Thursday, March 6th. Piper Sandler raised their price target on shares of Teva Pharmaceutical Industries from $23.00 to $30.00 and gave the stock an "overweight" rating in a report on Friday, January 17th. UBS Group lowered their price objective on Teva Pharmaceutical Industries from $30.00 to $27.00 and set a "buy" rating for the company in a research report on Thursday, January 30th. StockNews.com upgraded Teva Pharmaceutical Industries from a "hold" rating to a "buy" rating in a research report on Wednesday. Finally, Barclays lowered their price target on Teva Pharmaceutical Industries from $28.00 to $26.00 and set an "overweight" rating for the company in a report on Thursday, January 30th. One analyst has rated the stock with a hold rating and seven have issued a buy rating to the company's stock. Based on data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $23.43.

Teva Pharmaceutical Industries Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.